XML 89 R67.htm IDEA: XBRL DOCUMENT
v3.21.2

Business Combination - Narrative (Details) - USD ($) $ / shares in Units, shares in Millions |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 2 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 17, 2021 | Mar. 01, 2021 | Feb. 22, 2021 | Jan. 04, 2021 | Sep. 28, 2020 | Aug. 23, 2020 | Dec. 30, 2019 | Nov. 21, 2019 | Oct. 01, 2019 | Aug. 01, 2019 | Oct. 01, 2018 | Nov. 30, 2019 | Sep. 30, 2019 | Sep. 28, 2019 | Sep. 25, 2021 | Jun. 26, 2021 | Sep. 25, 2021 | Sep. 26, 2020 | Mar. 28, 2020 | Nov. 20, 2019
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,281,600,000 |  | $ 3,281,600,000 | $ 2,657,900,000 |  |
Contingent consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,300,000 |  | 16,300,000 | 0 |  |
Intangible assets, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,659,200,000 |  | 1,659,200,000 | 1,307,500,000 |  |
Portion allocable to fair value of noncontrolling interest |  |  |  |  |  |  |  | $ 8,600,000 |  |  |  |  |  |  |  |  |  |  |  |
Mobidiag Oy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price | $ 729,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology | 285,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships | 20,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade names | 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill | $ 432,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Decrease In Research And Development In Process |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 29,000,000 |  |  |  |  |
Mobidiag Oy | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mobidiag Oy | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate | 19.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mobidiag Oy | Developed Technology | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period | 8 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mobidiag Oy | Developed Technology | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period | 12 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mobidiag Oy | Customer Relationships | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mobidiag Oy | Customer Relationships | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mobidiag Oy | Trade names | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period | 8 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mobidiag Oy | Trade names | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period | 12 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biotheranostics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  | $ 231,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  | 18.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology |  |  | $ 160,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade names |  |  | 2,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  | $ 80,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Diagenode |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  | $ 155,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology |  | $ 69,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  | 9,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  | $ 83,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Diagenode | Developed Technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  | 14.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Diagenode | Customer Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  | 13.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Somatex Medical Technologies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  | $ 62,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology |  |  |  | 38,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  |  |  | 1,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade names |  |  |  | 900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  | 32,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net acquired tangible assets and liabilities |  |  |  | $ 9,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
NXC Imaging |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  | $ 5,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
NXC Imaging | Customer Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acessa Health |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  | $ 162,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  |  |  | 18.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology |  |  |  |  |  | $ 127,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade names |  |  |  |  |  | 1,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  | 49,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  | 81,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in contingent consideration liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (6,700,000) |  |  |
Acessa Health | Holdback |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Health Beacons |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 19,700,000 |  |  |  |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,200,000 |  | 6,200,000 |  |  |
Holdback |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,300,000 |  | 2,300,000 |  |  |
Intangible assets, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,700,000 |  | 10,700,000 |  |  |
Acquired tangible assets and liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,800,000 |  | 2,800,000 |  |  |
Alpha Imaging |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  | $ 18,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 900,000 |  | $ 900,000 |  |  |
Holdback |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |
SuperSonic Imagine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  | 69,300,000 |  | $ 18,200,000 |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12.00% |  |
Developed technology |  |  |  |  |  |  |  | 38,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  |  |  |  |  |  |  | 4,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Trade names |  |  |  |  |  |  |  | 3,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  |  | $ 34,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting interests acquired |  |  |  |  |  |  |  |  |  | 46.00% |  |  |  |  |  |  |  |  |  | 50.00%
Cash tender offer price per share |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.50 |  |  |  |  |  |  |
Acquired shares |  |  |  |  |  |  |  | 7.6 |  |  |  |  |  |  |  |  |  |  |  |
Additional purchase consideration |  |  |  |  |  |  |  | $ 12,600,000 |  |  |  |  |  |  |  |  |  |  |  |
Ownership of outstanding shares (as a percent) |  |  |  |  |  |  |  | 78.00% |  |  |  |  |  |  |  |  |  |  |  |
Equity interest in acquiree (as a percent) |  |  |  |  |  |  |  |  |  | 46.00% |  |  |  |  | 100.00% |  | 100.00% |  |  |
Remeasurement gain |  |  |  |  |  |  |  | $ 3,200,000 |  |  |  |  |  |  |  |  |  |  |  |
Portion allocable to equity method investment |  |  |  |  |  |  |  | 17,900,000 |  |  |  |  |  |  |  |  |  |  |  |
Portion allocable to newly acquired shares |  |  |  |  |  |  |  |  |  |  |  | $ 12,600,000 |  |  |  |  |  |  |  |
Portion allocable to loan repaymnet |  |  |  |  |  |  |  | $ 30,200,000 |  |  |  |  |  |  |  |  |  |  |  |
Additional outstanding shares purchased (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4.8 |  | 1.1 |  |
Additional outstanding shares purchased, amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 8,500,000 |  | $ 1,800,000 |  |
SuperSonic Imagine | Other Income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income (loss) from equity method investments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,300,000 |  |  |  |  |  |
SuperSonic Imagine | Customer Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  |  |  | 9 years |  |  |  |  |  |  |  |  |  |  |  |
SuperSonic Imagine | Trade names |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  |  |  | 8 years 7 months 6 days |  |  |  |  |  |  |  |  |  |  |  |
SuperSonic Imagine | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  |  |  | 9 years |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  | $ 12,500,000 |  | $ 120,100,000 |  |  |  |  |  |  |  |  |
Developed technology |  |  |  |  |  |  |  |  |  |  | 83,100,000 |  |  |  |  |  |  |  |  |
Trade names |  |  |  |  |  |  |  |  |  |  | 2,700,000 |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  |  |  |  |  | 31,100,000 |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  |  |  |  |  | $ 14,000,000 |  |  |  |  |  |  |  | $ 1,500,000 |
Payment period for contingent consideration |  |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |
Focal Therapeutics | Trade names |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  |  |  |  |  |  | 13 years |  |  |  |  |  |  |  |  |
Focal Therapeutics | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average amortization period |  |  |  |  |  |  |  |  |  |  | 11 years |  |  |  |  |  |  |  |  |
Focal Therapeutics | In-process research and development | Minimum | Measurement Input, Discount Rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  |  |  |  |  |  |  |  | 15.50% |  |  |  |  |  |  |  |  |
Focal Therapeutics | In-process research and development | Maximum | Measurement Input, Discount Rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  |  |  |  |  |  |  |  | 16.50% |  |  |  |  |  |  |  |  |

X
- Definition Additional purchase consideration + References No definition available. + Details
Name: | holx_AdditionalPurchaseConsideration
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business Acquisition, Cash Tender Offer Price Per Share + References No definition available. + Details
Name: | holx_BusinessAcquisitionCashTenderOfferPricePerShare
Namespace Prefix: | holx_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Additional Shares Acquired, Shares + References No definition available. + Details
Name: | holx_BusinessCombinationAdditionalSharesAcquiredShares
Namespace Prefix: | holx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Additional Shares Acquired, Value + References No definition available. + Details
Name: | holx_BusinessCombinationAdditionalSharesAcquiredValue
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Consideration Transferred, Portion Allocable To Equity Method Investment + References No definition available. + Details
Name: | holx_BusinessCombinationConsiderationTransferredPortionAllocableToEquityMethodInvestment
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Consideration Transferred, Portion Allocable To Fair Value Of Noncontrolling Interest + References No definition available. + Details
Name: | holx_BusinessCombinationConsiderationTransferredPortionAllocableToFairValueOfNoncontrollingInterest
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Consideration Transferred, Portion Allocable To Loan Repayment + References No definition available. + Details
Name: | holx_BusinessCombinationConsiderationTransferredPortionAllocableToLoanRepayment
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Consideration Transferred, Portion Allocable To Newly Acquired Shares + References No definition available. + Details
Name: | holx_BusinessCombinationConsiderationTransferredPortionAllocableToNewlyAcquiredShares
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Ownership Percentage + References No definition available. + Details
Name: | holx_BusinessCombinationOwnershipPercentage
Namespace Prefix: | holx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Period for Payment of Contingent Consideration Liability + References No definition available. + Details
Name: | holx_BusinessCombinationPeriodforPaymentofContingentConsiderationLiability
Namespace Prefix: | holx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Decrease In Research And Development In Process + References No definition available. + Details
Name: | holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDecreaseInResearchAndDevelopmentInProcess
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships + References No definition available. + Details
Name: | holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCustomerRelationships
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Technology + References No definition available. + Details
Name: | holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDevelopedTechnology
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value + References No definition available. + Details
Name: | holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValue
Namespace Prefix: | holx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Trade Names + References No definition available. + Details
Name: | holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTradeNames
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business Combination, Shares Acquired + References No definition available. + Details
Name: | holx_BusinessCombinationSharesAcquired
Namespace Prefix: | holx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Holdback + References No definition available. + Details
Name: | holx_Holdback
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liabilities assumed at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_MobidiagOyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=holx_DevelopedTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_BiotheranosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_DiagenodeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_SomatexMedicalTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_NXCImagingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_AcessaHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=holx_ContingentHoldbackMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_HealthBeaconsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_AlphaImagingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_SuperSonicImagineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_FocalTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |